Cargando…

CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity

A large proportion (40–60%) of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer do not benefit from trastuzumab treatment, potentially due to the lack of complement-dependent cytotoxicity (CDC) activation. In the present study, the effect of complement decay...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yu, Yang, Ya-Jun, Wang, Zhu, Liao, Juan, Liu, Mei, Zhong, Xiao-Rong, Zheng, Hong, Wang, Yan-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588148/ https://www.ncbi.nlm.nih.gov/pubmed/28928834 http://dx.doi.org/10.3892/ol.2017.6555

Ejemplares similares

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59
por: Zhang, Ronghua, et al.
Publicado: (2019)

Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization
por: Li, Yujia, et al.
Publicado: (2018)

Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease
por: Eldewi, Dalia Mahmoud, et al.
Publicado: (2019)

Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease
por: Mishra, Nitesh, et al.
Publicado: (2019)

Specific Acquisition of Functional CD59 but Not CD46 or CD55 by Hepatitis C Virus
por: Ejaz, Asim, et al.
Publicado: (2012)

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
por: Rodríguez, Cristina E., et al.
Publicado: (2015)

Increased Expression of Complement Regulators CD55 and CD59 on Peripheral Blood Cells in Patients with EAHEC O104:H4 Infection
por: Dammermann, Werner, et al.
Publicado: (2013)

miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55
por: Fan, Yu, et al.
Publicado: (2022)

Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients
por: Kurtoǧllu, Ayşegül Uǧur, et al.
Publicado: (2017)

Bispecific mAb(2) Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
por: Stadlbauer, Katharina, et al.
Publicado: (2022)

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1
Publicado: (1995)

Production of Multiple Transgenic Yucatan Miniature Pigs Expressing Human Complement Regulatory Factors, Human CD55, CD59, and H-Transferase Genes
por: Jeong, Young-Hee, et al.
Publicado: (2013)

The immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin
por: Kapka-Skrzypczak, Lucyna, et al.
Publicado: (2015)

NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
por: Son, Sung Wook, et al.
Publicado: (2022)

Beyond the Role of CD55 as a Complement Component
por: Dho, So Hee, et al.
Publicado: (2018)

Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59
por: Brennan, Kieran, et al.
Publicado: (2022)

Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59
por: Heider, Susanne, et al.
Publicado: (2016)

Blockade of complement activation in bullous pemphigoid by using recombinant CD55-CD46 fusion protein
por: Qiao, Pei, et al.
Publicado: (2021)

Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids
por: Gaykema, Lonneke H., et al.
Publicado: (2023)

Value of CD16/CD66b/CD45 in comparison to CD55/CD59/CD45 in diagnosis of paroxysmal nocturnal haemoglobinuria: An Indian experience
por: Kotru, Mrinalini, et al.
Publicado: (2017)

Anaemia & expression levels of CD35, CD55 & CD59 on red blood cells in Plasmodium falciparum malaria patients from India
por: Mahajan, R.C., et al.
Publicado: (2011)

Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid
por: Qiao, Pei, et al.
Publicado: (2017)

Increased internalization of complement inhibitor CD59 may contribute to endothelial inflammation in obstructive sleep apnea
por: Emin, Memet, et al.
Publicado: (2016)

CD59 Regulation by SOX2 Is Required for Epithelial Cancer Stem Cells to Evade Complement Surveillance
por: Chen, Jianfeng, et al.
Publicado: (2016)

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo
por: Liu, Jianuo, et al.
Publicado: (2005)

Expression of Membrane Complement Regulatory Proteins Crry and CD55 in Normal Rats
por: Kato, Chie, et al.
Publicado: (2013)

Functional Dissection of the Dominant Role of CD55 in Protecting Vesicular Stomatitis Virus against Complement-Mediated Neutralization
por: Asok Kumar, Nisha, et al.
Publicado: (2021)

Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein, CD59
por: Bodian, Dale L., et al.
Publicado: (1997)

Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation
por: Sandomenico, Annamaria, et al.
Publicado: (2023)

A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria
por: Yıldız, Abdülkerim, et al.
Publicado: (2014)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Overexpression of CD55 correlates with tumor progression and poor prognosis in gastric stromal tumors
por: Yin, Xiaonan, et al.
Publicado: (2019)

The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon
por: Asimakopoulos, John V., et al.
Publicado: (2014)

CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells
por: Xiong, Lijuan, et al.
Publicado: (2016)

CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and-independent mechanisms
por: Longhi, M Paula, et al.
Publicado: (2007)

Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
por: Tsao, Li-Chung, et al.
Publicado: (2022)

Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.
por: Koretz, K., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_lvm4497hdgdlhks1vbhhlcshut